- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non small cell lung cancer (NSCLC)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 1.5MB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 1.5MB)
Osimertinib – November 2023
Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso®
Last updated
13 March 2024